Deciphering TICRR's oncogenic landscape in pancreatic adenocarcinoma: molecular insights and clinical implications

解读TICRR在胰腺腺癌中的致癌图谱:分子层面的见解和临床意义

阅读:2

Abstract

BACKGROUND: Pancreatic adenocarcinoma (PAAD) has a poor prognosis due to late diagnosis and limited treatment options. While protein-coding genes are known to contribute to disease pathogenesis, their specific roles require further investigation. METHODS: We analyzed RNA-seq and clinical data from 179 PAAD patients in TCGA to examine TICRR (TOPBP1 Interacting Checkpoint And Replication Regulator). Prognostic analyses included survival and risk assessment. Complementary cell-based experiments explored TICRR and associated non-coding RNAs (ncRNAs). Multi-omics profiling examined potential relationships between TICRR expression and tumor microenvironment features. RESULTS: Higher TICRR expression showed association with poorer survival outcomes. Experimental modulation of MIR659 and AC074099.1 expression appeared to influence malignant phenotypes in vitro. Multi-omics data suggested potential links between TICRR-associated molecular changes and features of immune evasion and genomic instability. CONCLUSION: Our findings suggest possible connections between TICRR expression and PAAD progression. The observed phenotypic changes following ncRNA modulation may indicate their involvement in related oncogenic processes. These preliminary observations warrant further investigation into potential regulatory relationships between TICRR and associated ncRNAs, which could inform future therapeutic strategies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12672-025-03803-6.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。